Company Overview of MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. Its products include Margetuximab, a monoclonal antibody that targets human epidermal growth factor receptor 2-expressing tumors, including breast, gastroesophageal, bladder, and other cancers; MGA271, an Fc-optimized monoclonal antibody for various solid tumor types; MGD006, a humanized dual affinity re-targeting (DART) molecule for the treatment of hematologic cancers; and MGD007, a DART protein to treat colorectal cancer. The company’s products also comprise Teplizumab, a humanized anti-CD3 monoclon...
9640 Medical Center Drive
Rockville, MD 20850
Founded in 2000
Key Executives for MacroGenics, Inc.
Chief Executive Officer
Total Annual Compensation: $456.1K
Chief Financial Officer
Total Annual Compensation: $306.7K
Senior Vice President of Clinical Development
Total Annual Compensation: $148.6K
Compensation as of Fiscal Year 2013.
MacroGenics, Inc. Key Developments
MacroGenics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 07:30 AM
Jan 12 15
MacroGenics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 07:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Scott Koenig, Chief Executive Officer, President and Director.
MacroGenics, Inc. Enters Collaboration and License Agreement with Janssen Biotech, Inc
Dec 22 14
On December 19, 2014, MacroGenics, Inc. entered into a transaction with Janssen Biotech, Inc. and its affiliate, Johnson & Johnson Innovation JJDC, Inc. comprised of collaboration and license agreement with Janssen. Under the terms of the Collaboration Agreement, Janssen will be fully responsible for developing the company's proprietary product candidate, MGD011, following submission of the investigational new drug application for MGD011 with the U.S. Food and Drug Administration, and is obligated to use commercially reasonable efforts to undertake certain development, regulatory and commercialization activities. MGD011 incorporates the company's proprietary platform for Dual-Affinity Re-Targeting to simultaneously target CD19, a cell-surface protein found on B cells including certain neoplastic B cells, and CD3, a protein found on T cells. This product candidate will be developed for the treatment of various leukemias and lymphomas that express the CD19 protein. MGD011 is currently in pre-clinical development. Under the terms of the Collaboration Agreement, the company will receive a $50 million upfront license fee from Janssen. Assuming successful development and commercialization, the company could receive up to an additional $575 million in clinical, regulatory and commercialization milestone payments as well as double-digit royalties on any global net sales.
MacroGenics, Inc.(NasdaqGS:MGNX) added to NASDAQ Biotechnology Index
Dec 22 14
MacroGenics, Inc. will be added to the NASDAQ Biotechnology Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|